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A central hypothesis for the limited capacity for adult
central nervous system (CNS) axons to regenerate is
the presence of myelin-derived axon growth inhibi-
tors, the role of which, however, remains poorly
understood. We have conducted a comprehensive
genetic analysis of the three major myelin inhibitors,
Nogo, MAG, and OMgp, in injury-induced axonal
growth, including compensatory sprouting of unin-
jured axons and regeneration of injured axons. While
deleting any one inhibitor in mice enhanced sprout-
ing of corticospinal or raphespinal serotonergic
axons, there was neither associated behavioral
improvement nor a synergistic effect of deleting all
three inhibitors. Furthermore, triple-mutant mice
failed to exhibit enhanced regeneration of either
axonal tract after spinal cord injury. Our data indicate
that while Nogo, MAG, and OMgp may modulate
axon sprouting, they do not play a central role in
CNS axon regeneration failure.INTRODUCTION
A fundamental problem that impedes functional recovery from
central nervous system (CNS) injuries is the failure of damaged
adult CNS axons to regenerate. This limited ability for axon
regeneration has been attributed to the growth inhibitory nature
of CNSmyelin (Gonzenbach and Schwab, 2008), the glial scar at
the injury site (Silver andMiller, 2004), an insufficiency of growth-
promoting/permissive factors and/or tissue bridges (Lu and
Tuszynski, 2008), and a lack of neuron-intrinsic growth potential
(Moore et al., 2009; Park et al., 2008). Despite considerable
advances in our understanding of all four areas, it is yet not
known what is primarily responsible for the lack of significant
axon regeneration in the adult CNS.
Among the contributors to CNS regeneration failure, the
molecular pathways underlying myelin inhibition of axon growth
have been most extensively characterized (Filbin, 2003; Yiu and
He, 2006). Threemajor myelin-derived inhibitors have been iden-
tified: Nogo (or Rtn4), MAG (myelin-associated glycoprotein),
and OMgp (oligodendrocyte myelin glycoprotein, or Omg);
each possesses potent inhibitory activity on neurite outgrowthin vitro. Extensive biochemical and cell culture studies have led
to the current working model where the three inhibitors signal
through multiple neuronal receptors including the shared
ligand-binding receptors NgR1 and PirB as well as coreceptors
such as p75NTR, TROY, and LINGO-1, with downstream effec-
tors such as Rho and Rho-associated kinase (ROCK; Atwal
et al., 2008; Yiu and He, 2006). Despite these elegantly eluci-
dated biochemical pathways, the role of Nogo, MAG, and
OMgp and that of myelin inhibitors in general in axon regenera-
tion in vivo remain poorly understood.
Much of the initial evidence implicating Nogo in axon regener-
ation came from experiments showing that administration of the
IN-1 antibody, which recognizes—but is not specific to—Nogo
(Caroni and Schwab, 1988), promoted axon regeneration of the
corticospinal tract (CST) after experimental spinal cord injury
(Bro¨samle et al., 2000; Schnell and Schwab, 1990). More spe-
cific antibodies produced more limited effects (Liebscher et al.,
2005). Furthermore, experiments with a function-blocking pep-
tide that interferes with Nogo-NgR1 interaction generated mixed
results (GrandPre´ et al., 2002; Li and Strittmatter, 2003; Steward
et al., 2008a).
Genetic studies in mice have been applied to provide a more
definitive assessment of the role of myelin inhibitors in axon
regeneration (Zheng et al., 2006). However, no consistent and
robust regeneration has been reported in mice lacking Nogo
(Cafferty et al., 2007; Dimou et al., 2006; Kim et al., 2003; Lee
et al., 2009b; Simonen et al., 2003; Steward et al., 2007; Zheng
et al., 2003). Enhanced axon growth in an OMgp mutant has
been reported, but it was not clear whether the injury models
specifically assessed regeneration or sprouting (see below),
and the CST did not regenerate in this mutant (Ji et al., 2008).
For MAG, genetic studies have not implicated any significant
role in injury-induced axonal growth (Bartsch et al., 1995). These
observations, together with the ability of Nogo, MAG, and OMgp
to signal through common receptors, have led to the hypothesis
that the three inhibitors play redundant roles in restricting axon
regeneration (Filbin, 2003; Liu et al., 2006; Zheng et al., 2006).
To assess the combined contribution of all three inhibitors,
we generated a Nogo/MAG/OMgp triple null mutant and investi-
gated its axon growth phenotype after injury. We applied four
different injury models to examine the compensatory sprout-
ing of uninjured axons and the regeneration of injured axons in
two different axonal tracts. Results from these experiments illus-
trate that while modulating axon sprouting, the three major
myelin-derived axon growth inhibitors do not play a central role
in axon regeneration failure in the injured CNS.Neuron 66, 663–670, June 10, 2010 ª2010 Elsevier Inc. 663
Neuron
Myelin Inhibitors in Injury-Induced Axonal GrowthRESULTS
Generation and Baseline Characterization
of Nogo/MAG/OMgp Triple Null Mutants
We have recently described the generation of a Nogo deletion
mutant and an OMgp null mutant (Lee et al., 2009a; Lee et al.,
2009b). The Nogo deletion mutant differs from all other Nogo
mutants published in that it is the only Nogo null that is fully viable
and lacks the expression of all known Nogo isoforms including
Nogo-A,B,C, and thus would allow for unequivocal assessment
of all Nogo isoforms (Lee et al., 2009b). Given the unusual loca-
tion of the OMgp gene in the intron of the Neurofibromin 1 gene
(NF1), we designed the OMgpmutation tominimize any effect on
NF1 expression (Lee et al., 2009a). The Nogo andOMgpmutants
were bred to a previously characterized MAG null mutant
(Li et al., 1994) to obtain Nogo/MAG/OMgp triple null mutants
in a mixed background with 129S7 and C57BL/6 (see Supple-
mental Experimental Procedures available online), which proved
viable, fertile, and exhibited no gross morphological defects.
Western blot analysis on total brain protein extracts confirmed
the absence of Nogo-A, MAG, and OMgp proteins and further
indicated that the expression of their common receptors, NgR1
and PirB, was not altered in the triple mutants (Figure 1A).
In baseline behavioral assays, Nogo mutants exhibited subtle
defects in openfield locomotion asassessedby theBassomouse
scale (BMS) (Bassoetal., 2006),whilebothMAGandOMgpsingle
mutants exhibited defects in a rotarod test (Figures 1B and 1C).
However, deleting all three proteins did not appear to cause an
overt synergistic effect. In addition, none of the mutants showed
any defect in a gridwalk or forepaw preference test (Figures 1D
and 1E). In subsequent experiments, wherever appropriate, we
used a behavioral assay that showed no orminimal baseline defi-
cits as the primary behavioral measure following injury.
The Effects of Deleting One or All Three Inhibitors
on Neurite Outgrowth In Vitro
We first asked whether deleting all three myelin inhibitors would
lead to an increased release of myelin inhibition of neurite
outgrowth as compared with deleting Nogo alone. As expected,
neurite outgrowth from postnatal day 7 cerebellar granule
neurons was inhibited by wild-type (WT) myelin (Figures 2A,
2B, and 2E). Consistent with previous studies using Nogo-A,B-
or Nogo-A-deficient myelin (Kim et al., 2003; Simonen et al.,
2003; Zheng et al., 2003), this inhibition was partially released
on Nogo null myelin (Figures 2C and 2E). However, this reduction
in neurite inhibition was not enhanced by deleting all three inhib-
itors from the myelin (Figures 2D and 2E). MAG-deficient myelin
was as inhibitory as WT myelin, whereas OMgp deficient myelin
displayed a trend for reduced inhibition that was not statistically
significant (Figure 2E).
To determine whether this result can be extended to another
neuronal type, we measured neurite outgrowth from dissoci-
ated adult dorsal root ganglion (DRG) neurons or DRG explants
grown on spinal cord cryosections, a more physiologically rele-
vant substrate than purified myelin. Similar to cerebellar
neurons on myelin substrates, neurite outgrowth from DRG
neurons was enhanced on triple null spinal cord sections to the
same extent as on Nogo null sections in comparison to WT664 Neuron 66, 663–670, June 10, 2010 ª2010 Elsevier Inc.controls (Figures 2F–2K). MAG null sections were as inhibitory
as WT controls whereas, again, OMgp null sections displayed a
trend for reduced inhibitory activity that did not reach statistical
significance (Figures 2H and 2K). Taken together, these in vitro
assays indicate that, for the two neuronal types analyzed, delet-
ing all three inhibitors, Nogo, MAG, and OMgp, does not lead to
significantly more neurite outgrowth than deleting Nogo alone.
The Effects of Deleting One or All Three Inhibitors
on Serotonergic Axon Sprouting
To ascertain whether deleting the three inhibitors enhances
injury-induced axonal growth in vivo, we used four different injury
models to assess axon regeneration or compensatory sprouting
of twomajor descending pathways: the raphespinal serotonergic
tract and the corticospinal tract (CST). These two axonal tracts
are known to possess different growth capabilities after injury:
the CST is very refractory to regeneration while the raphespinal
serotonergic tract exhibits a high growth capacity following injury
(Hollis et al., 2009; Saruhashi et al., 1996). Here, we define regen-
eration as growth of injured axons beyond the injury site and
sprouting as growth of uninjured axons for relatively shorter
distances in response to an injury elsewhere in theCNS.Wechar-
acterize both phenomena as injury-induced axonal growth.
We first analyzed compensatory sprouting of raphespinal
serotonergic axons across the midline following a lateral hemi-
section. These descending axons originate in the raphe nuclei
in the brainstem, travel down the spinal cord, andmodulate loco-
motion (Schmidt and Jordan, 2000). Because serotonergic
axons have a high growth capacity following injury, and because
sprouting across the midline does not involve growth through
a glial scar, another potent inhibitory barrier to regeneration
(Silver and Miller, 2004), we reasoned that this model would be
among the most likely to reveal enhanced injury-induced axonal
growth in mice deficient in myelin inhibitors.
Mice were subjected to a right lateral hemisection (illustrated
in Figure S1A) at the eighth thoracic (T8) vertebral level, leading
to depletion of serotonergic input in the caudal ipsilateral spinal
cord. Sprouting of uninjured serotonergic axons from the contra-
lateral side, as assessed by 5-hydroxytryptamine (or 5-HT)
immunoreactivity, was analyzed at the lumbar enlargement
below the level of injury. Four weeks after injury, MAG and OMgp
single mutants, but not Nogo mutants, exhibited an elevated
level (2-fold) of 5-HT immunoreactivity on the denervated
side as compared with WT mice. However, this was not further
enhanced in the triple mutants (Figures 3A–3C). This enhanced
sprouting was not due to any gross developmental defects of the
raphespinal serotonergic tract in themutants (Figures S1B–S1D).
Despite the increased serotonergic axon sprouting, MAG, OMgp
and triple mutants did not perform significantly better than WT
controls in the gridwalk (Figure 3D) or the BMS open field test
(data not shown). Thus, deleting MAG or OMgp enhances
compensatory sprouting of serotonergic axons while there is no
additive or synergistic effect of deleting all three inhibitors.
The Effects of Deleting One or All Three Inhibitors
on Corticospinal Axon Sprouting
To determine whether an axonal tract that is more refractory to
injury-induced growth displays increased sprouting in the
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Figure 1. Basic Characterization of Nogo/MAG/OMgp Triple
Mutants
(A) Western blot analysis of Nogo-A, MAG, OMgp, NgR1, and PirB on total
brain extracts from WT and Nogo/MAG/OMgp mutant mice. WT, wild-type;
KO, knockout (mutant); Ab, Antibody. Representative results are shown from
1 out of 2–3 independent biological replicates that gave similar results.
(B–E) Baseline behavioral performance of WT, single and triple mutants in
various locomotor tasks used in the spinal cord injury models (B–D, n = 17–24)
or the forepaw preference test used in the pyramidotomy model (E, n = 8–11).
*p < 0.05 compared with WT. One-way ANOVA with Tukeys posttest.
All error bars are SEM.
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Myelin Inhibitors in Injury-Induced Axonal Growthmutants, we applied a pyramidotomymodel to study compensa-
tory sprouting of uninjured CST axons across the spinal cord
midline. The CST originates from the sensorimotor cortex and
crosses the midline at the medullary pyramids before the main
cohort of CST axons course down the contralateral spinal cord
through the ventral part of the dorsal column in rodents and
innervate the contralateral gray matter. The CST was severed
unilaterally at the (right) medullary pyramid above the pyramidal
decussation (the point of CST axons crossing the midline), re-
sulting in complete denervation of the contralateral (left) spinal
cord from corticospinal neurons in the right sensorimotor cortex
(Figures 4A and 4B). The neuronal tracer biotinylated dextran
amine (BDA) was injected into the left sensorimotor cortex to
trace uninjured CST axons (Figure 4C) corresponding to the right
forelimb area. BDA labeling efficiency did not significantly differ
between different genotypes (Figures S2A–S2C). To further
control for variations in BDA labeling among individual animals,
the axonal counts in the contralateral graymatter (as an indicator
of axon sprouting) were normalized against the total number of
BDA labeled CST axons in themedullary pyramid for each animal
(see Supplemental Experimental Procedures). The lesion was
verified by the unilateral loss of PKCg immunoreactivity in the
spinal cord (Figures S2D–S2F), which marks the main CST.Pyramidotomy in WT mice induced spontaneous sprouting of
CST axons across the midline from the intact to the contralateral
side (Figures 4D, 4E, and 4J). Consistent with a previous study
using a Nogo-A,B mutant line (Cafferty and Strittmatter, 2006),
Nogo null mutants exhibited enhanced CST sprouting, albeit at
levels lower than expected based on the previous report (Figures
4F and 4K). Whereas OMgp mutants did not differ significantly
from WT controls, MAG mutants unexpectedly displayed
reduced CST sprouting (Figures 4G, 4H and 4K). In line with
this observation, the degree of CST sprouting in the triple
mutants was similar to that of WT mice (i.e., intermediate
between Nogo and MAG mutants), suggesting antagonistic
effects of deleting Nogo and MAG (Figures 4I, 4J, and 4K).
Despite the spectrum of CST sprouting phenotypes in various
mutants, recovery of forepaw preference during rearing behavior
after pyramidotomy (Starkey et al., 2005) did not differ signifi-
cantly among genotypes (Figure 4L).
Because the reduced CST sprouting in MAG mutants was
unexpected, we sought to confirm this finding with a different
injury model. In the dorsal hemisection model used to assess
CST axon regeneration (illustrated in Figure S4A, described
below), CST axons rostral to the injury site often sprouted into
the contralateral gray matter in WT mice (Figures S3A and
S3B). Consistent with reduced CST sprouting in the pyramidot-
omy model, CST axons rostral to the injury site in MAG mutants
also displayed reduced sprouting into the contralateral gray
matter after dorsal hemisection (Figures S3C–S3E). This was
not due to a difference in BDA labeling efficiency, because (1)
the average total number of CST axons labeled in the medullary
pyramids did not differ between the two genotypes (Figure S3F),
and (2) interanimal variability in labeling efficiency was further
controlled by normalizing the axonal density on transverse spinal
cord sections against the total number of BDA labeled CST
axons in themedullary pyramid. Taken together, genetic deletion
of Nogo increases sprouting of CST axons while deleting MAG
decreases CST sprouting, and there is no synergistic effect of
deleting all three proteins.
Lack of Enhanced Corticospinal or Raphespinal
Serotonergic Axon Regeneration in Nogo/MAG/OMgp
Triple Mutants
Axon regeneration has been pursued as a major goal when tar-
geting myelin-derived axon growth inhibitors (Gonzenbach and
Schwab, 2008), but genetically deleting Nogo, MAG, or OMgp
in mice leads to no or little enhancement of axon regeneration
(Bartsch et al., 1995; Ji et al., 2008; Kim et al., 2003; Lee et al.,
2009b; Simonen et al., 2003; Steward et al., 2007; Zheng et al.,
2003). To determine whether deleting all three inhibitors would
promote axon regeneration after spinal cord injury, we analyzed
CST and serotonergic axon regeneration in the triple mutants
following a dorsal hemisection and a complete transection of
the spinal cord respectively. Following a T8 dorsal hemisection
injury (illustrated in Figure S4A), unilateral BDA tracing was per-
formed to assess the regeneration of CST axons corresponding
to the hindlimb area. In both WT controls and triple mutants,
injured CST axons exhibited typical retraction from the injury site
and were rarely detected at the injury site or more caudal regions
(Figures 5A and 5B), which was confirmed with quantification ofNeuron 66, 663–670, June 10, 2010 ª2010 Elsevier Inc. 665
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Figure 2. Lack of a Synergistic Effect of
Deleting Nogo, MAG, and OMgp in
Releasing Myelin Inhibition In Vitro
(A–E) Representative images (A–D) and quantifica-
tion (E) of neurite outgrowth from WT postnatal
mouse cerebellar granule neurons (CGNs) plated
on laminin or CNS myelin from mice of various
genotypes.
(F–K) Representative images (F, G, I, and J) and
quantification (H and K) of neurite outgrowth from
dissociated adult WT mouse dorsal root ganglion
(DRG) neurons (F, G, and H) or DRG explants
(I, J, and K) cultured on top of adult spinal cord
sections of various genotypes.Max length, longest
neurite length. Results are shown from one out of
three experiments that gave similar results.
All error bars are SEM. n > 120 (E); n > 30 (H); n > 25
(K). @p < 0.05 compared with Laminin control.
*p < 0.05 compared with WT. One-way ANOVA
with Tukeys posttest. Scale bars: 100 mm (A–D, I,
and J), 50 mm (F and G).
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Myelin Inhibitors in Injury-Induced Axonal Growththe axon density along the rostral-caudal axis (Figure 5C).
Consistent with the lack of enhanced regeneration, behavioral
analyses did not reveal any significant differences between the
two genotypes in the gridwalk (Figure 5D), open field locomotion
or rotarod tests (Figures S4C and S4D) throughout the 6 week
survival period. To address the possibility that deleting MAG
could counteract any detectable regeneration-promoting effect
of deleting Nogo and OMgp, we also analyzed the three single-
mutant lines individually. We found no evidence of significantWT 
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666 Neuron 66, 663–670, June 10, 2010 ª2010 Elsevier Inc.CST regeneration after dorsal hemisec-
tion in Nogo, MAG, or OMgp single
mutants (Figure S5), confirming previous
studies (Bartsch et al., 1995; Ji et al.,
2008; Lee et al., 2009b). Thus, deletingany one inhibitor (Nogo, MAG, or OMgp) or the three inhibitors
altogether does not promote CST axon regeneration.
To study raphespinal serotonergic axon regeneration, we sub-
jected the triple mutants to a complete transection spinal cord
injury (illustrated in Figure S4B). Because serotonergic axons
descend throughout the dorsal and ventral spinal cord, this
model is required to completely eliminate these axons en route to
caudal segments. Lesion effectiveness was verified by a GFAP-
negative area at the lesion epicenter in serial sections throughoutFigure 3. Sprouting of Raphespinal Seroto-
nergic Axons and Locomotor Recovery after
Lateral Hemisection
(A and B) Representative images of transverse
sections of lumbar spinal cord immunostained for
serotonergic (5-HT) axons in a WT mouse (A) and
a triple mutant (B).
(C) Quantification of 5-HT immunoreactivity at the
lumbar enlargement ipsilateral to the lateral hemi-
section (n = 9–13). *p < 0.05 compared with WT,
one-way ANOVA with Tukeys posttest.
(D) Gridwalk behavioral recovery. Two-way
repeated-measures ANOVA with Bonferonni
posttest.
All error bars are SEM. Scale bars: 500 mm. See
also Figure S1.
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Figure 4. Sprouting of CST Axons and
Recovery of Forepaw Preference after
Pyramidotomy
(A) Illustration of the pyramidotomy model (dorsal
view). Arrow, site of pyramidotomy; shaded area,
the plane of section for (C); arrowhead, axonal
sprouts from the uninjured side.
(B) Representative ventral view of the boxed area in
(A) to show the site of pyramidotomy (arrow).
(C) Representative transverse spinal cord section
labeled for uninjured CST axons at the cervical
enlargement following pyramidotomy. Solid rect-
angle represents the region quantified in (J) and (K).
(D–I) Representative higher magnification images
corresponding to the dotted area in (C) from mice
of various genotypes.
(J and K) Quantification of labeled uninjured CST
axons at cervical levels comparing uninjured and
injured mice (J) or comparing all genotypes
following pyramidotomy (K). Rectangle in (K) indi-
cates the data points depicted for injured mice in
(J). Uninjuredmice: n = 2–3mice/genotype; pyrami-
dotomized mice: n = 8–11 mice/genotype.
(L) Recovery of forepaw preference. *p < 0.05
compared with WT; #p < 0.05 compared with
uninjured. Two-way repeated-measure ANOVA
with Bonferonni posttest.
All error bars are SEM. Scale bars: 500 mm (C),
50 mm (D–I). See also Figures S2 and S3.
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Myelin Inhibitors in Injury-Induced Axonal Growththe entire width of the spinal cord (Figures 5E, 5F, and data not
shown). Serotonergic axons were observed approaching the
injury site and exhibited the highest density immediately rostral
to the injury site in both WT and triple-mutant mice. Quantifica-
tion revealed a significantly higher level of 5-HT immunoreactivity
just rostral to injury in the triple mutants (Figure 5G), indicative of
enhanced serotonergic axon sprouting consistent with data from
the lateral hemisectionmodel (Figures 3A–3C). However, seroto-
nergic axons did not traverse the injury site to any significant
extent in either WT controls or triple mutants (Figures 5E–5G).
In addition, mice of both genotypes displayed similarly minimum
open field locomotor recovery as assessed by the BMS score
(Figure 5H). Thus, deleting all three inhibitors does not promote
raphespinal serotonergic axon regeneration.
DISCUSSION
The failure of axon regeneration in the injured adult CNS is
a fundamental problem in neuroscience. Myelin inhibition of
axon growth has been proposed as a major mechanism ofNeuron 66, 663–CNS axon regeneration failure. However,
considerable controversies exist re-
garding the role of myelin inhibitors in
regeneration in vivo (Bartsch et al., 1995;
Cafferty et al., 2007; Kim et al., 2003;
Simonen et al., 2003; Steward et al.,
2007; Zheng et al., 2003). Here, we pre-
sented data from rigorous and compre-
hensive genetic analyses of Nogo, MAG,and OMgp, the three major myelin inhibitors, in injury-induced
axonal growth. By applying different injury models, we investi-
gated two distinct forms of axonal growth: compensatory
sprouting of uninjured axons and regeneration of injured axons.
By comparing the phenotypes of mice lacking one or all three
inhibitors, we addressed the question of functional redundancy
among the three inhibitors. In addition, our analysis encom-
passed two axonal tracts with different growth capabilities.
Results from these experiments provided important new insights
on the role of Nogo, MAG, and OMgp in injury-induced axonal
growth and have implications on therapeutic development for
spinal cord injury by targeting these molecules.
First and foremost, our data demonstrate that, contrary to
what has been proposed, Nogo, MAG, and OMgp are not
primarily responsible for the limited axon regeneration in the
adult CNS. Axon regeneration is defined here as the growth of
injured axons beyond the injury site. Using a dorsal hemisection
and a complete transection injury model, respectively, we found
that deleting Nogo, MAG, and OMgp did not promote CST or
serotonergic axon regeneration. Furthermore, no improved670, June 10, 2010 ª2010 Elsevier Inc. 667
Figure 5. Lack of Regeneration of CST and Raphespi-
nal Serotonergic Axons in Triple-Mutant Mice
(A–D) Representative images (A and B) and quantification (C;
n = 10–12) of traced CST axons in sagittal sections, and grid-
walk behavioral recovery (D) following a dorsal hemisection
injury. Arrows indicate the injury site. Rostral is to the left.
(E–H) Representative images (E and F) and quantification (G;
n = 4–7) of 5-HT immunostained serotonergic axons (red) cos-
tained for GFAP (blue) in sagittal sections, and locomotor
recovery as assessed by the BMS open field test (H) following
a complete transection spinal cord injury. *p < 0.05 compared
with WT, two-way repeated-measures ANOVA with Bonfer-
onni posttest.
All error bars are SEM. Scale bars: 500 mm. See also Figures
S3, S4, and S5.
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Myelin Inhibitors in Injury-Induced Axonal Growthbehavioral recovery was observed in Nogo/MAG/OMgp triple
mutants after injury. In the complete transection model, the
lack of enhanced serotonergic axon regeneration can be poten-
tially explained by the inability of any regenerating axons to
penetrate the glial scar, the complex role of which is highlighted
by the recent discovery of the opposing effects of macrophages
and NG2+ cells on axonal dieback in addition to the more exten-
sively characterized roles of reactive astrocytes (Busch et al.,
2010). In the case of dorsal hemisection, however, the spared
ventral spinal cord could serve as a tissue bridge through which
CST axonsmay regenerate (Steward et al., 2008b). Thus, another
and perhaps more general mechanism, such as the neuron-
intrinsic growth potential (Park et al., 2008), may be the deter-
mining factor here. It has long been hypothesized that Nogo,
MAG, and OMgp are functionally redundant in restricting axon
regeneration (Filbin, 2003; Liu et al., 2006; Zheng et al., 2006),
which predicted a synergistic effect of deleting all three inhibi-
tors. Our results demonstrate that the limited axon regeneration
after deleting any one inhibitor cannot be simply attributed to the
proposed functional redundancy among the three inhibitors.668 Neuron 66, 663–670, June 10, 2010 ª2010 Elsevier Inc.Compared with our data on axon regeneration,
our finding that deleting a single inhibitor enhances
the compensatory sprouting of uninjured axons
expands current literature indicating a role for
Nogo in axon sprouting (Cafferty and Strittmatter,
2006; Raineteau et al., 2001; Thallmair et al.,
1998). Sprouting is defined here as the growth of
uninjured axons in response to an injury elsewhere
in the CNS. It should be noted that compensatory
axon sprouting can occur spontaneously after
injury (Weidner et al., 2001). Our data indicate that
such naturally occurring axon sprouting can be
modulated by targeting not just Nogo, but also
MAG or OMgp. While deleting any one inhibitor
enhanced the sprouting of CST or serotonergic
axons, deleting all three inhibitors did not further
enhance sprouting. This lack of a synergistic effect
may be due to a lack of functional redundancy
among the three inhibitors, and/or a ceiling
effect—and thus indicates a limitation—of modu-
lating the myelin-associated inhibitory environ-ment. Surprisingly, deleting MAG even reduced CST axon
sprouting. This may reflect a role for MAG in axon protection
(Nguyen et al., 2009), growth promotion (Hasegawa et al.,
2004), or simply the possibility that deleting MAG diminishes
tracer transport to the distal extremities of axons. Regardless,
the reduced CST sprouting in MAG single mutants presents
a caveat in interpreting the data on CST sprouting in the Nogo/
MAG/OMgp triple mutants where deleting Nogo and MAG may
have counteracting effects. It remains possible that deleting
Nogo and OMgp but not MAGmay be more effective in inducing
CST sprouting than deleting Nogo alone. Future work on Nogo/
OMgp double mutants is required to address this question.
A second caveat in interpreting the sprouting effect in the various
mutants is the possible effects of genetic background variations
on injury-induced axonal growth (Ma et al., 2004). The original
single mutant mice used to establish the triple-mutant line had
mixed background of 129S7 and C56BL/6. Although we took
precautions against genetic drifts (see Supplemental Experi-
mental Procedures), our use of ‘‘cousins’’ rather than siblings as
controls leaves open the possibility of strain-dependent effects.
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practically impossible since intercrosses between triple hetero-
zygous mice would only have a yield of 1/128 for any particular
genotype. An alterative approach would be backcrossing each
of the single mutant to a pure strain followed by intercrosses to
generate triple-mutant mice. We are currently performing these
backcrosses to address this issue in future.
Both axon regeneration and axon sprouting can lead to func-
tional recovery (Bradbury and McMahon, 2006). In this regard,
however, we found that enhanced axonal sprouting in the
mutants was not associated with a detectable enhancement in
behavioral recovery. This result indicates that themodest degree
of enhancement in axon sprouting (50%–100% increase)
observed in the mutants is insufficient to elicit robust functional
benefits. Therefore, the physiological significance, if any, of the
enhanced sprouting after deleting Nogo, MAG and/or OMgp
remains to be established.
While deleting Nogo promoted CST axon sprouting, deleting
MAG or OMgp promoted serotonergic axon sprouting. This
apparent differential sensitivity of an axonal tract to the deletion
of different myelin inhibitors could simply reflect its differential
exposure to different inhibitors. The three myelin inhibitors are
differentially localized in the myelin and at axon-glial contact
sites (Huang et al., 2005; Huber et al., 2002; Trapp, 1990). It is
thus conceivable that this differential cellular and subcellular
localization among the three myelin inhibitors may render axons
of different characteristics (e.g., whether myelinated or not)
a differential sensitivity to their growth-modulating effects.
Further studies are required to determine the exact mechanisms
for such differential sensitivity and to rule out the possibility of
injury model-specific effects.
While this paper was in press, a similar genetic study by the
Strittmatter group on Nogo-A,B/MAG/OMgp was published
(Cafferty et al., 2010). Both papers agree on a general role for
the three proteins in axon sprouting and a more prominent role
for Nogo in contributing to the inhibitory nature of CNS myelin
in vitro and in inhibiting CST sprouting in vivo. However, there
are notable differences between the two studies. Cafferty et al.
observed significantly enhanced CST regeneration and loco-
motor recovery in their Nogo-A,B single mutants and Nogo-
A,B/MAG/OMgp triple mutants after injury; we did not (in either
our Nogo null mutants or our Nogo/MAG/OMgp triple null
mutants). They observed a synergistic effect of deleting all three
inhibitors both in vitro and in vivo; we did not. In fact, our data
indicate that MAG may even be protective or growth-promoting
for CST axons. The two studies also differ in the assessment of
the relative contribution among the three proteins in inhibiting
5-HT axon sprouting. Genetic backgrounds and the exact nature
of the mutations (at least for Nogo and OMgp) might affect
mutant phenotypes, although in the case of Nogo we previously
assessed the very same Nogo-A,B gene trap mutant line
analyzed by Cafferty et al. and failed to observe any enhance-
ment of CST regeneration (Lee et al., 2009b). It should be noted
that the Nogo mutation we used in the current study was a null
mutation for all Nogo isoforms (Lee et al., 2009b), whereas the
one they used was not; the OMgp mutation we used did not
disrupt the expression of the NF1 gene (Lee et al., 2009a),
whereas it was not clear if this was the case for the one usedby Cafferty et al. There are also differences in the injury models
used. We used dorsal hemisection and complete transection
to study the regeneration of CST and 5-HT axons, respectively,
and pyramidotomy and lateral hemisection to study the sprout-
ing of CST and 5-HT axons, respectively. Cafferty et al. used
a single dorsal hemisection model to study regeneration/sprout-
ing of both CST and 5-HT axons, and in the case of 5-HT axons
they did not distinguish between ‘‘regeneration’’ and ‘‘sprout-
ing.’’ Thus, the definition of regeneration versus sprouting, the
nature of the mutations, the injury model used, and likely the
exact method to produce the injury may impact experimental
outcomes. Future work is required to resolve these issues.
In summary, our data demonstrate that deleting the three
major myelin inhibitors is insufficient to promote the regeneration
of injured axons in the adult CNS. While deleting Nogo, MAG,
and/or OMgp may enhance the sprouting of uninjured axons,
there was no associated behavioral improvement. Thus, the
therapeutic potential of targeting these three molecules alone
to promote axonal repair after CNS injury may be limited.
EXPERIMENTAL PROCEDURES
Experimental Procedures are available as Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
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